Results 51 to 60 of about 117,898 (292)
Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2. [PDF]
, 2016 CML is effectively treated with tyrosine kinase inhibitors (TKIs). However, the efficacy of these drugs is confined to the chronic phase of the disease and development of resistance to TKIs remains a pressing issue.
Calabretta, Bruno +10 more
core +2 more sources
Imatinib-induced interstitial pneumonitis – a literature review and case report [PDF]
, 2020 Imatinib is generally well tolerated, with mild common side effects such as nausea and vomiting, diarrhea, muscle cramps, fatigue, skin rash and edema; however, pulmonary complications are uncommon. A 73-year-old woman undergoing one month treatment with
Ciulei, George +12 more
core +2 more sources
Advanced Healthcare Materials, EarlyView.AngioPlate384 is a 384‐well open‐top platform that automates production of more than 100 miniaturized, perfusable blood vessels embedded in hydrogel and supported by stromal cells. Stromal‐endothelial co‐culture strengthens blood vessel barrier function and yields responses useful for translational planning. Scalable and automation‐ready, it suits drug
Dawn S. Y. Lin +14 more
wiley +1 more source
Long-term follow-up of Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in children and adolescents managed at a single institution over a 20-year period [PDF]
, 2005 Chronic myeloid leukaemia (CML) is rare in childhood. In our Institution we managed 30 consecutive Ph+CML patients aged
DE CUIA MR +7 more
core +1 more source
Kelvin Probe Force Microscopy in Bionanotechnology: Current Advances and Future Perspectives
Advanced Materials, EarlyView.Kelvin probe force microscopy (KPFM) enables the nanoscale mapping of electrostatic surface potentials. While widely applied in materials science, its use in biological systems remains emerging. This review presents recent advances in KPFM applied to biological samples and provides a critical perspective on current limitations and future directions for
Ehsan Rahimi +4 more
wiley +1 more source
BMC Cancer, 2010 Background Breast cancer treatment is based on a combination of adjuvant chemotherapy followed by radiotherapy effecting intracellular signal transduction. With the tyrosine kinase inhibitors new targeted drugs are available.
Weigel Marion T +10 more
doaj +1 more source
Current Issues in Molecular Biology, 2022 Imatinib has been the first and most successful tyrosine kinase inhibitor (TKI) for chronic myeloid leukemia (CML), but many patients develop resistance to it after a satisfactory response. Glutathione (GSH) metabolism is thought to be one of the factors
Priyanka Singh +3 more
doaj +1 more source
Advanced Science, EarlyView.Histone 3 lysine18 lactylation (H3K18la) drives heterogeneous nuclear ribonucleoprotein C (HNRNPC) overexpression, activating autophagy to mediate gemcitabine resistance by stabilizing TNF receptor‐associated factor 6 (TRAF6) mRNA. Concurrently, HNRNPC stabilizes aldehyde dehydrogenase 1 family member A3 (ALDH1A3) mRNA, which enhances glycolysis and ...
Xi‐Tai Huang +9 more
wiley +1 more source
Haematologica, 2019 Standard first-line therapy of chronic myeloid leukemia is treatment with imatinib. In the randomized German Chronic Myeloid Leukemia-Study IV, more potent BCR-ABL inhibition with 800 mg (‘high-dose’) imatinib accelerated achievement of a deep molecular ...
Christian Michel +60 more
doaj +1 more source
Frontiers in Pharmacology, 2020 Long-term use of imatinib is effective and well-tolerated in children with chronic myeloid leukaemia (CML) yet defining an optimal dosing regimen for imatinib in younger patients is a challenge.
Jeffry Adiwidjaja +3 more
doaj +1 more source